Skip to main navigation

Press Releases

Year

Mar 14, 2024

Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024

Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site

Mar 11, 2024

Autolus Therapeutics announces publication in Blood Cancer Journal

Feb 29, 2024

Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024

Feb 22, 2024

Autolus Therapeutics announces publication in Nature Communications

Feb 08, 2024

Autolus Announces Pricing of Underwritten Offering

Feb 08, 2024

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Jan 23, 2024

Autolus Therapeutics announces publication in ACS Chemical Biology

Jan 22, 2024

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Jan 10, 2024

Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors

Pagination

First page
Previous page
Page 1
Page 2
Current page 3

Displaying 21 - 30 of 30